Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | TIMP3 | P35625 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | CASR | P41180 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.40 |
| ▸ | ENTPD3 | O75355 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6073527 | 0.83 | CASP6 (0.60) | CASP6KMT2AMEN1ALDH1A1EDNRA | |
| SCHEMBL8018981 | 0.82 | CASP6 (0.72) | CASP6KMT2AMEN1ALDH1A1HSD17B10 | |
| SCHEMBL3301802 | 0.81 | CASP6 (0.66) | CASP6KMT2AMEN1TIMP3ALDH1A1 | |
| SCHEMBL9723988 | 0.78 | CASP6 (0.48) | CASP6KMT2AMEN1TIMP3ALDH1A1 | |
| SCHEMBL1857055 | 0.77 | KMT2A (0.59) | CASP6KMT2AMEN1ALDH1A1EDNRA | |
| SCHEMBL4650417 | 0.77 | CASP6 (0.64) | CASP6KMT2AMEN1ALDH1A1RXFP1 | |
| SCHEMBL8589696 | 0.77 | ENPP2 (0.49) | CASP6KMT2AALDH1A1HSD17B10TTR | |
| SCHEMBL28247278 | 0.77 | CASP6 (0.49) | CASP6KMT2AALDH1A1RXFP1MAPT | |
| SCHEMBL3032086 | 0.76 | TTR (0.56) | CASP6KMT2AMEN1TIMP3ALDH1A1 | |
| SCHEMBL31151117 | 0.76 | TTR (0.56) | CASP6KMT2AMEN1TIMP3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9084734-B2 | Peptide personal care compositions and methods for their use | DANISCO US INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-8293784-B2 | α-amino acid derivatives for improving solubility | MERCK PATENT GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20120014885-A1 | Personal Care Compositions and Methods for Their Use | DANISCO US INC. | 2012-01-19 | — | — | US | disclosed |
| EP-2344531-A1 | MODIFIED VARIANT BOWMAN BIRK PROTEASE INHIBITORS | Danisco US Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20110152292-A1 | SALTS COMPRISING A PYRIMIDINECARBOXYLIC ACID DERIVATIVE FOR COSMETIC USE | MERCK PATENT GESELLSCHAFT (DE) | 2011-06-23 | — | — | US | disclosed |
| US-7943662-B2 | For skin/hair light protection; cosmetics | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-05-17 | — | — | US | disclosed |
| US-20110039924-A1 | ALPHA-AMINO ACID DERIVATIVES FOR IMPROVING SOLUBILITY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-02-17 | — | — | US | disclosed |
| US-7772181-B2 | Personal care compositions comprising modified variant Bowman Birk Protease Inhibitors | DANISCO US INC. (US) | 2010-08-10 | — | — | US | disclosed |
| WO-2010044786-A1 | MODIFIED VARIANT BOWMAN BIRK PROTEASE INHIBITORS | DANISCO US INC., GENENCOR DIVISION (US) | 2010-04-22 | — | — | WO | disclosed |
| US-20100092409-A1 | PERSONAL CARE COMPOSITIONS COMPRISING MODIFIED VARIANT BOWMAN BIRK PROTEASE INHIBITORS | DANISCO US INC. | 2010-04-15 | — | — | US | disclosed |
| US-20090098074-A1 | Keratin-Binding Effector Molecules Containing Reactive Dyes | BASF SE (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20080075684-A1 | Keratin-Binding Polypeptides | BASF AKTIENGESELLSCHAFT (DE) | 2008-03-27 | — | — | US | disclosed |
| EP-1880007-A2 | PERSONAL CARE COMPOSITIONS AND METHODS FOR THEIR USE | GENENCOR INTERNATIONAL, INC. (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006121610-A2 | PERSONAL CARE COMPOSITIONS AND METHODS FOR THEIR USE | GENENCOR INTERNATIONAL, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| US-20050276764-A1 | Topical use of bis-arylimidazo[1,2-a]thiolane derivatives | BEIERSDORF AG | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098074-A1 | Keratin-Binding Effector Molecules Containing Reactive Dyes | KRT18, KLK3, KLKB1 | CASP6 2411/4885KMT2A 2796/4885MEN1 4346/4885 |
| US-20110152292-A1 | SALTS COMPRISING A PYRIMIDINECARBOXYLIC ACID DERIVATIVE FOR COSMETIC USE | NUDT1, PPIP5K2, ENPP1 | CASP6 1353/4885KMT2A 4325/4885MEN1 3242/4885 |
| US-20120014885-A1 | Personal Care Compositions and Methods for Their Use | CUTA, VEGFA, BDNF | CASP6 2302/4885KMT2A 3229/4885MEN1 2582/4885 |
| US-20100092409-A1 | PERSONAL CARE COMPOSITIONS COMPRISING MODIFIED VARIANT BOWMAN BIRK PROTEASE INHIBITORS | SERPINB1, CPB1, HABP2 | CASP6 2047/4885KMT2A 3756/4885MEN1 843/4885 |
| US-20050276764-A1 | Topical use of bis-arylimidazo[1,2-a]thiolane derivatives | ITCH, TRPA1, TPH1 | CASP6 2750/4885KMT2A 1642/4885MEN1 4693/4885 |
| US-20110039924-A1 | ALPHA-AMINO ACID DERIVATIVES FOR IMPROVING SOLUBILITY | SLC7A1, AADAT, DNPEP | CASP6 4151/4885KMT2A 2905/4885MEN1 2988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.